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More than 2700 stem cell researchers from 44 different countries attended the 6th ISSCR Annual Meeting in
Philadelphia from June 11 to 14, 2008. Themeeting covered awide range of topics discussed in 7 plenary and
16 concurrent sessions and presented in 1150 posters.One of the themes of this year’s meeting, highlighted by the
Presidential Symposium on Developmental Biology, was the
translation of the principles of lineage commitment defined in
developmental biology models to stem cell biology. With this
report, we’ve attempted to review this subject as well as many
others covered in this year’s outstanding meeting.
Regulation of Lineage Commitment in the Early Embryo
and during Embryonic Stem Cell Differentiation
Lineage Development in the Early Embryo
During embryogenesis, pluripotent cells gradually restrict their
developmental potential as they progress toward terminal cell
fates to establish tissues and organ systems. Lineage specifica-
tion during embryogenesis is achieved by the coordinated inter-
action of extrinsic cues with cell-intrinsic signaling pathways that
ultimately lead to the activation of tissue-specific genetic
programs. Defining and recreating these regulatory programs
in culture is essential for the efficient generation of tissues from
pluripotent cells. One of the earliest stages of lineage diversity
in the embryo is marked by the establishment of the three
germ layers—ectoderm, mesoderm, and endoderm—during
the process of gastrulation. While many different regulators of
germ layer formation have been identified, recent studies by
the group of Elizabeth Robertson (University of Oxford) have
added another factor to the list in demonstrating that the T box
transcription factor eomesodermin (Eomes), previously shown
to be required for trophoblast development, plays a key role at
this early stage of lineage specification. By targeted deletion of
Eomes specifically in the epiblast of the embryo, Robertson
and colleagues showed that this T box transcription factor is
required for definitive endoderm formation and that this function
is mediated in a cell-autonomous fashion. Interestingly, its role
in mesoderm formation is quite different and appears to be at
the level of epithelium-to-mesenchyme transition and cell move-
ment, as in the absence of Eomes, the germ layer cells
are formed but are unable to delaminate and migrate from the
primitive streak (Arnold et al., 2008).
Following induction, the primary germ layer cells undergo pat-
terning and specification to generate the diverse array of line-
ages that participate in organ formation. Kenneth Zaret (Fox
Chase Cancer Center) provided an overview of liver and pan-creas formation from definitive endoderm, discussing the origins
of progenitors for these tissues as well as the cascade of signal-
ing pathways required for their specification. Pancreas derives
from both ventral and dorsal areas of the foregut endoderm,
whereas the liver forms from the medial and lateral regions of
only the ventral part (Zaret, 2008). Previous studies have shown
that the FGF and BMP signaling pathways play a role in liver and
pancreas development. Zaret highlighted the importance of the
temporal aspects of signaling in developmental biology and
showed that lateral ventral endoderm is exposed to FGF signal-
ing prior to the medial population during liver specification, that
BMP signaling is required only at the early patterning stages of
pancreas formation, and that sustained activin/nodal/TGFb
signaling may function to restrict the size of both the liver and
pancreatic progenitor populations.
Mesoderm specification to hematopoiesis was the focus of
the presentation given by Roger Patient (Weatherall Institute
of Molecular Medicine). Early in development the embryo is
faced with the challenge of rapidly generating differentiated
blood cells required for immediate survival as well as establish-
ing a program that will sustain lifelong hematopoiesis. Most ev-
idence to date suggests that these demands are met through
the development of distinct primitive and definitive hematopoi-
etic programs that are initiated at different sites and times in the
embryo. Using both the Xenopus and Zebrafish model systems,
Patient reported on studies that investigated the signaling path-
ways that regulate hematopoietic development, focusing pri-
marily on the definitive system that is derived from lateral plate
mesoderm and initiates in the dorsal aorta of the embryo. From
detailed studies using both gain- and loss-of-function mutants,
his group was able to establish the sequential requirements for
BMP, FGF, hedgehog, VEGF, and Notch signaling during the
progression of mesoderm though a putative hemangioblast to
hemogenic endothelium to the hematopoietic stem cell (HSC).
Shin-Ichi Nishikawa (Riken Center for Developmental Biology)
presented an update on the work of his laboratory focused on
the origin of the adult hematopoietic system. He provided evi-
dence indicating that the entire hematopoietic system, primitive
and definitive, is specified within a narrow window of time, early
in development. These findings raise interesting questions with
respect to the origin of definitive hematopoiesis and suggestCell Stem Cell 3, September 11, 2008 ª2008 ISSCR 259
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Translating Developmental Biology
to Embryonic Stem Cells
Detailed knowledge of the cellular and molecular mechanisms
involved in stem cell generation and fate decisions during em-
bryonic development is critical for successful in vitro generation
of tissue-specific stem, progenitor, and mature cells from plu-
ripotent cells. Janet Rossant (The Hospital for Sick Children)
stressed the importance of understanding the developmental
status of individual pluripotent stem cell populations, as this
could influence their differentiation potential and ultimately their
future use in cell therapy. She showed that mouse and human
embryonic stem cells (hESCs) respond differently to the ectopic
expression of Cdx2, a transcription factor associated with tro-
phoblast formation. The response of the hESCs was more similar
to the response of postimplantation epiblast cells than to that ob-
served with mouse ESCs. Overexpression assays such as this
may aid in assigning different pluripotent cell types to the correct
developmental stage and in establishing possible differences
between stem cell lines. Continuing along these lines, Cheryle
Se´guin (Rossant laboratory, The Hospital for Sick Children) re-
ported on studies involving the expression of Sox7 and Sox17
in hESCs, with the goal of directing their differentiation to extra-
embryonic and definitive endoderm fates, respectively. Progen-
itor populations displaying characteristics of the two types of
endoderm were generated in the absence of any additional
inducing molecules, opening the possibility that this ectopic
expression strategy may be useful in generating differentiated
populations from pluripotent stem cells (Se´guin et al., 2008).
Employing known embryonic signaling pathways in controlled
culture conditions, Gordon Keller and colleagues (McEwen Cen-
ter for Regenerative Medicine) have successfully generated
hematopoietic, cardiovascular, and endodermal tissues in vitro
from both mouse and human ESCs (Murry and Keller, 2008). A
key observation in these studies was that the hematopoietic
and cardiovascular lineages separate early in development in
these differentiation cultures. In the mouse system these line-
ages develop from two temporally distinct Flk1+ cell popula-
tions. While comparable temporal differences have not been es-
tablished in human ESC cultures, the hematopoietic and cardiac
lineages do segregate to distinct KDR populations distinguished
by coexpression of C-KIT. The findings from these different ESC-
based studies reveal the emergence of endothelial cells from at
least three different stages: endothelial cells derived from the he-
mangioblast (the common progenitor for blood and endothelial
cells), endothelial cells from cardiomyocyte precursors, and
endothelial cells that arise in close association with endoderm
(Valerie-Gouon Evans, Keller laboratory).
As advances are made in our ability to generate differentiated
cell types from human pluripotent cells, the development of
appropriate preclinical models will be essential to test their func-
tion. The importance of selecting an appropriate animal model
system was highlighted by the presentation of Christine Mum-
mery (Leiden University Medical Center), who showed that hu-
man ESC-derived cardiomyocytes did not functionally integrate
following injection into infarcted mouse hearts and provided only
transient improvement in the function of the recipient hearts. One
major problem with the use of the rodent model for such studies260 Cell Stem Cell 3, September 11, 2008 ª2008 ISSCRis the dramatic difference (almost 10-fold) in the heart rate
between rodents and humans. Larger animals with slower heart
rates comparable to those of humans may provide more appro-
priate models to study the capacity of human ESC-derived
cardiomyocytes to repair damaged hearts.
In addition to endoderm and mesoderm lineages, several pre-
sentations reported on progress in generating ectodermal deriv-
atives from hESCs. Yechiel Elkabetz (Studer laboratory, Sloan-
Kettering Cancer Center) described the prospective isolation of
a novel neural stem cell named R-NSC from human and mouse
ESC-derived neural rosette cells. (Elkabetz et al., 2008). Similar
cells were isolated from mouse neural plate-stage embryos. In
contrast to previously described NSCs, the R-NSC have a rela-
tively high proliferative potential and no glial bias in their differen-
tiation potential, making them better suited for cell therapy, pro-
vided their differentiation potential can be harnessed in vitro.
Benjamin Reubinoff (Hadassah-Hebrew University Medical Cen-
ter) reported on the generation of retinal pigment epithelial (RPE)-
like cells from human ESCs. Cells generated following a multistep
differentiation culture displayed many characteristics of RPE
cells, including pigmentation, the expression of appropriate
markers, a polygonal RPE-like morphology, and phagocytic ca-
pacity. Following intraocular injection into a rat model of retinal
degeneration, the human ESC-derived cells integrated into the
RPE layer of the host and led to some improvements in retinal
function in these animals.
Insights into Stem Cell Regulation and Development
from ESCs
ESCs provide a readily accessible source of pluripotent cells for
studies investigating the molecular and epigenetic mechanisms
that maintain an undifferentiated state and the changes that ac-
company lineage restriction. Previous studies with mouse ESCs
led to the identification of Oct4, Sox2, and Nanog as important
regulators of pluripotency. Thomas Zwaka (Baylor College of
Medicine) described the addition of a novel pluripotency factor
named Ronin to this list. (Dejosez et al., 2008). This factor acts
independently of Oct4, Sox2, and Nanog and is a member of
the THAP domain-containing family of transcription factors as-
sociated with epigenetic silencing. Ronin is required for ESC
growth and, when expressed ectopically, enables ESCs to
self-renew under conditions that normally induce differentiation.
At the molecular level, Ronin acts as a suppressor of transcrip-
tion, likely through its binding of HCF-1, a key transcriptional
regulator. As HCF-1 is associated with both activating and
repressive histone modifications, these findings raise the inter-
esting possibility that Ronin, interacting with HCF-1, is involved
in establishing bivalent chromatin marks in ESCs.
Bivalentchromatinmarkshaverecentlybeenreportedona large
number of promoters inhuman and mouse ESCs. These marks are
thought to keep developmentally regulated genes silent in ESCs
while keeping them poised for transcription with the onset of line-
age specification (Mendenhall and Bernstein, 2008). However,
some of the bivalent marks in ESCs are found at loci that play no
role in development. Bradley Bernstein (Massachusetts General
Hospital and Broad Institute) reviewed recent developments that
indicate that loci of key developmental genes can be separated
from the loci of housekeeping genes on the basis of differential
Polycomb complex binding. Recently, it was reported that the bi-
valently marked developmentally regulated genes are in fact
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(the Hebrew University of Jerusalem) described studies indicating
that the ESC genome is transcriptionally hyperactive compared to
ESC-derived neural precursor cells (Efroni et al., 2008). This low-
level global transcriptional activity of ESCs is accompanied by
an increased expression of the chromatin remodeling and general
transcription machinery. The authors conclude that pluripotent
cells are characterized by elevated global transcriptional activity
and low-level expression of lineage-specific genes and propose
that lineage commitment is accompanied by a restriction of the
transcribed portion of the genome.
Wolf Reik (The Babraham Institute) discussed the role of epi-
genetic regulation in lineage allocation in the preimplantation
embryo. Through genome-wide screens, Reik and colleagues
identified an Ets family member as a potential regulator of the tro-
phoblast lineage in these cells and speculate that it functions as
a gatekeeper between the embryonic and trophoblast lineages.
The importance of chromatin remodeling factors in ESC differ-
entiation was further addressed by Patrick Paddison (Cold
Spring Harbor Laboratory). In a collaborative effort with Ihor
Lemischka (Mount Sinai School of Medicine), he found that
core components of the Swi/SNF complex play a critical role in
dismantling the pluripotency network as ESCs differentiate. Le-
mischka presented a multilevel, molecular, and dynamic analysis
of changes that accompany the short hairpin RNA-mediated
depletion of Nanog protein from mouse ESCs. Downregulation
of this protein was followed by dramatic alterations in the epige-
nome, transcriptome, and the nuclear proteome. Surprisingly,
a large proportion of changes at the protein level were not ac-
companied by corresponding changes in their encoding mRNAs.
In addition to the well-established transcriptional regulation,
there is now good evidence that microRNAs also play a role in
the control of ESC growth and differentiation (Stadler and Ruo-
hola-Baker, 2008). Richard Gregory (Children’s Hospital Boston)
reported on the regulation of let-7, a microRNA that is upregulated
as ESCs are induced to differentiate. He found that lin-28, a devel-
opmentally regulatedRNA-bindingprotein, selectively inhibited the
processing of the primary let-7 transcript (Viswanathan et al., 2008).
Somatic Stem Cells: Identity, Potential,
and Regulation
HSCs
The defining characteristics of HSCs are their ability to self-re-
new and their capacity to generate progeny of multiple lineages
(multipotency). Although these characteristics are often used for
all HSCs, there is now considerable evidence indicating that this
stem cell population displays heterogeneity with respect to these
properties. Connie Eaves (Terry Fox Laboratories) presented an
overview of HSC biology with emphasis on pre- and postnatal
age-related changes. Notably, the cell-cycle activity of HSCs
decreases abruptly between 3 to 4 weeks of age (Bowie et al.,
2007). The potential of the HSC also changes; stem cells from fe-
tal liver display balanced myeloid/lymphoid potential, whereas
subpopulations of those from the adult acquire a bias to the my-
eloid lineages (Dykstra et al., 2007). The underlying mechanisms
governing these changes are not fully understood but likely
include epigenetic regulation.
The longevity of the HSC compartment in vivo relies on the abil-
ity to maintain quiescence of HSCs, preventing exhaustion andminimizing the risk of malignant transformation. To investigate
the quiescent state of HSCs, Kateri Moore (Mount Sinai School
of Medicine) studied their label retention capacity, using a dou-
ble-transgenic mouse model in which expression of a histone
H2B-GFP fusion protein is controlled by a tetracycline-inducible
transactivator. With this approach, she found that HSCs are pres-
ent in the quiescent label-retaining population. The mechanisms
regulating HSC quiescence were revisited by Hiromitsu Nakauchi
(University of Tokyo), Toshio Suda (Keio University School of
Medicine), and Lingheng Li (Stowers Institute), who reported
that the quiescence of HSCs is maintained by interactions with
the osteoblastic niche through Tie2 and c-mpl signaling and N-
cadherin-mediated adhesion and is associated with repression
of AKT-FOXO signaling and inhibition of the cell cycle by
p57Kip2. Suda showed that treatment of recipient mice with an-
tioxidants or a p38 MAPK inhibitor prevented the HSC exhaustion
usually associated with serial transplantation. Consistent with the
notion that oxidative stress influences the entry of HSCs into the
cell cycle, he reported that the HIF1a- and FOXO3a-deficient
mice have a decreased proportion of quiescent HSCs. Nakauchi
showed that stimulation of quiescent HSCs by growth factors re-
sults in rapid clustering of lipid rafts known to play a role as signal-
ing centers. This clustering augments cytokine signals to the
levels that are sufficient to induce HSCs into cell cycle. The quies-
cent state of HSCs could be maintained ex vivo by inhibiting lipid
raft clustering by TGF-b.
Novel insights into the niche cells governing HSC behavior in
the bone marrow were provided by Olaia Naveiras (Daley labora-
tory, Children’s Hospital Boston), who presented evidence indi-
cating that marrow adipocytes may serve as negative regulators
for HSCs. Differentiation of the OP9 stromal cells into adipocytes
dramatically reduced their ability to support hematopoiesis in
culture, and regions of bone marrow with a high content of adi-
pocytes appear to be less supportive of HSCs and progenitors
than those areas with a low number. Further insights into the
complexity of microenvironmental control of HSCs was provided
by Tsvee Lapidot (Weizmann Institute of Science), who dis-
cussed the emerging evidence for a role of the autonomous
nervous system in regulating HSC migration and mobilization.
Stem Cells from Nonhematopoietic Lineages
In addition to the well-characterized stem cells of the hematopoi-
etic system, stem cells have been identified in other sites, includ-
ing the skeletal muscle, the skin, and neural tissues.
Skeletal muscle satellite cells have been identified as a source
of muscle stem cells that contribute to muscle repair in experi-
mental disease models. Amy Wagers (Joslin Diabetes Center) re-
ported on the prospective isolation of skeletal muscle stem cells
from the satellite cell pool, on the basis of a unique surface
marker profile that distinguishes them from the nonmyogenic
myofiber-associated cells. A high proportion of the isolated cells
appeared committed to the myogenic lineage in vitro. Upon
intramuscular transplantation into mdx mice that model aspects
of human Duchenne’s muscular dystrophy, muscle function was
restored proportional to the level of engraftment. Importantly,
they also reconstituted the satellite cell niche, indicative of their
stem cell function (Cerletti et al., 2008). Thomas Rando (Stanford
University) discussed the processes that affect muscle stem cell
function during aging and reviewed findings that this population
can be activated in heterochronic parabiotic mice,
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ulation. He also reported on studies suggesting that these effects
may be mediated through the activation of the Wnt signaling
pathway. While the satellite cell has long been recognized as
a progenitor for skeletal muscle, Giulio Cossu (San Raffaele Sci-
entific Institute) presented strong evidence that cells with peri-
cyte characteristics also display the capacity to generate this lin-
eage. Using a lineage tracing strategy, he demonstrated that
pericytes contributed to the formation of skeletal muscle, indi-
cating these cells constitute an alternative pathway of muscle
generation.
The skin, another tissue with a high turnover rate, has also long
been recognized to harbor stem cells. Fiona Watt (CambridgeUni-
versity) presented an update on recent work from her lab on the
epidermal stem cell niche. Analysis of different transgenic mouse
models, carrying normal or mutant adhesion molecules, showed
that the interaction of the epidermal stem cells with extracellular
matrix molecules was required to maintain the stem cell niche.
In addition, aberrant adhesion appeared to affect tumor formation
in an experimental model. The mechanism mediating this onco-
genic transformation is currently under investigation.
In contrast to the epidermal stem cell, little is known about the
existence of a dermal stem cell. Using transplant and wound-
healing experiments, Jeff Biernaskie (Miller Laboratory, Hospital
for Sick Children) showed that skin-derived precursor cells
(SKPs), a multipotent neural crest-like precursor population pre-
viously isolated from the dermis, represent dermal stem cells.
Moreover, he showed that these cells have the ability to induce
hair morphogenesis, and that this activity is maintained over time.
Another stem cell of the skin, the melanocyte stem cell in the
hair follicle bulge, has also been the subject of much study, as
their progeny are responsible for the pigmentation of hair. Mayumi
Ito (Cotsarelis Laboratory, University of Pennsylvania) showed
that melanocytes in the interfollicular dermis are also derived
from the bulge melanocyte stem cells. Using a lineage tracing ap-
proach in mice, she demonstrated that, following wounding or UV
irradiation, melanocytes from the bulge migrate to the epidermis,
where they can produce melanin (Ito et al., 2007).
An important area of stem cell research is the understanding of
the molecular mechanisms that govern self-renewal and cell-fate
decisions. A significant effort has focused on the role of tran-
scription factors in these processes. Yongchao Ma (Greenberg
laboratory, Children’s Hospital Boston) reported on the impor-
tance of phosphorylation of the basic helix-loop-helix (bHLH)
transcription factor Neurogenin 2 (Nrg2) in motor neuron cell de-
velopment. He presented evidence that phosphorylation of two
conserved serine residues in Nrg2 is critical for motor neuron
specification, but not for neurogenesis (Ma et al., 2008). Ma
concluded that this may be a general mechanism by which the
activities of bHLH and homeodomain factors may be spatiotem-
porally integrated in the specification of neurons. Sally Temple
(New York Neural Stem Cell Institute) described the character-
ization of novel stem cell populations derived from adult retinal
pigment epithelium (RPESCs). When cultured as spheres, these
RPESC-derived populations express markers shared with em-
bryonic stem cells, suggesting that they may contain pluripotent
cells. Preliminary studies presented indicate that these cultured
stem cells can generate diverse cell types that express markers
associated with ectoderm, endoderm, and mesoderm develop-262 Cell Stem Cell 3, September 11, 2008 ª2008 ISSCRment, suggesting that they are able to generate progeny of the
three germ layers. Comparable stem cells could be isolated
from eyes of both young and old cadavers as well as from
living patients, suggesting that they may represent a new source
of cells for replacement therapy.
Cancer Stem Cells
The term ‘‘cancer stem cell’’ defines the subpopulation of cells
within a tumor that is required to maintain it. The remaining cells
within the tumor are thought to represent progeny of this stem
cell population (Dalerba et al., 2007). It has only recently become
possible to isolate prospective cancer stem cells and to test
their function using xenogeneic transplantation assays. In such
assays, cancer stem cells are identified as tumor-initiating cells
that recreate the malignancy in the xenogeneic hosts. Using
this approach, tumor-initiating cells have been detected in
many hematological and solid tumors. In general, the frequency
of tumor-initiating cells tends to be very low, and the degree of
enrichment in phenotypically defined populations is often lim-
ited. One possible reason for the low frequency could relate to
the assay’s xenogeneic setting, with only a subset of the tumor
cells able to survive and/or function in this environment. Sean
Morrison (University of Michigan) reported on the influence of
the host environment on the frequency of tumor-initiating cells
in human metastatic melanoma. He showed that the frequency
of such cells increased dramatically if a more compromised re-
cipient is used, if the time following transplantation is extended,
and if the cells are coinjected with extracellular matrix protein
and mesenchymal cells. Following these treatments, the fre-
quency of tumor initiating cells increased from 1 in 100,000 cells
to 1 in 4 cells. These findings highlight the importance of optimiz-
ing the assay prior to initiating the study and suggest that either
the cancer stem cell paradigm does not apply to this particular
tumor, or that the fraction of cancer stem cells in metastatic
melanoma is very high. Yet, even in cases where the frequency
of tumor-initiating cells is much higher than that of stem cells
in normal tissues, their biological characteristics may differ
sufficiently from those of the remaining tumor cells to warrant
the development of strategies to specifically target them.
Although there is agreement in the field that the term ‘‘cancer
stem cell’’ defines a cell or cell population that sustains growth
of a tumor, this term has also been used to designate the normal
cell that underwent transformation and gave rise to the tumor.
Using a novel melanoma model in zebrafish, Richard White (Zon
laboratory, Dana Farber Cancer Institute) showed that activating
Braf mutations, which frequently occur in benign nevi, expand
crestin-expressing neural crest progenitors and subsequently
cause melanoma in adult fish. Thus, it is possible that the cell
type in which Braf mutations occur, i.e., neural crest precursors
versus mature melanocytes, determines whether a benign nevus
or a malignant melanoma will develop. This group also showed
that endothelin signaling is critical for the pathogenesis of mela-
noma in this model, lending support to the idea that, for many tu-
mors, lineage and stem/progenitor cell-specific therapeutic mo-
dalities can be and need to be developed based on the specific
developmental origin of the tumor. Along the same lines, Owen
Witte (University of California, Los Angeles) presented data
indicating that androgen receptor-ETS family fusion genes ex-
pressed in prostate cancer predominantly target prostate
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Hospital Boston) provided an overview on bronchoalveolar stem
cells (BASCs) that coexpress the clara cell marker CCSP, the al-
veolar marker SP-C, and the HSC marker Sca-1. Using a K-ras
transgenic model of lung cancer, she found that the BASC pop-
ulation was expanded in the developing tumors. Transplantation
studies revealed that both the Sca-1+ BASC cells as well as the
type II alveolar cells could propagate the tumor, demonstrating
that different populations function as the tumor-initiating cells in
this model. Judy Lieberman (Harvard Medical School) reported
her recent findings that Let-7 miRNA expression is reduced in
breast cancer stem cells. One target of let-7 was found to inhibit
differentiation when expressed ectopically in breast cancer stem
cell lines.
The strongest evidence for the existence of cancer stem cells
has been obtained from studies in leukemia (Hope et al., 2004). It
is now generally accepted that most, if not all, myeloid leukemias
contain a leukemia-initiating cell that would represent an impor-
tant target for therapy. Craig Jordan (University of Rochester)
showed that putative acute myeloblastic leukemia (AML) stem
cells are more resistant to chemotherapeutic agents than the re-
mainder of the leukemic population. Similar observations were
presented for breast cancer initiating cells (Judy Lieberman, Har-
vard Medical School). An attractive approach for developing
novel therapies is the identification of small molecules that show
selective activity on cancer or leukemic stem cells. Jordan re-
ported that two of such molecules, DMAPT, a parthenide analog,
and TDZD-8, a non-ATP competitive inhibitor of GSK-3b, show
some selectivity for leukemic stem cells. TDZD-8 killed cells
with extremely rapid kinetics, likely through disruption of mem-
brane structures. The cytotoxic effects of this compound
appeared restricted to hematological malignancies, again em-
phasizing the concept of lineage-specific therapies. The identifi-
cation of small molecules that target stem cell populations in neu-
roblastoma (Kristen Smith, Kaplan laboratory, The Hospital for
Sick Children), in mixed-lineage leukemia (Junping Wei, Mulloy
laboratory, Cincinnati Children’s Hospital Medical Center) and in
glioblastoma (John Yu., Cedars-Sinai Medical Center) was also
reported, indicating the broad potential of this approach.
Patient-specific therapies may also be required for the treat-
ment of leukemia. Dominique Bonnet (London Research Institute)
showed that the CD34/CD38 status of AML stem cells varies
among patients, indicating that the phenotype of the target cell
for therapy may differ from patient to patient. Irving Weissman
(Stanford University School of Medicine) described the properties
of acute myelogenous leukemia tumor-initiating cells or leukemia
stem cells (LSCs). The LSC properties included the activation of
proto-oncogenic steps and silencing of tumor suppressor genes,
combined with properties inherent to HSC and progenitors,
including the expression of ‘‘don’t eat me’’ molecules apparently
required for final passage in marrow to stem and progenitor
niches. Many of these represent potential new targets for tumor
therapy.
Reprogramming
Until the recent discoveries of Yamanaka and colleagues
(Takahashi and Yamanaka, 2006), nuclear reprogramming was
achieved through the transfer of somatic nuclei to enucleated
eggs or oocytes. This year’s keynote speaker, Sir John Gurdon,a pioneer in nuclear reprogramming, provided an overview of the
field and highlighted key questions to be addressed in the future.
He reported that egg cytoplasm is able to rapidly demethylate
promoters and activate transcription of genes found in pluripo-
tent stem cells including Oct4, Nanog, and Sox2. While the re-
programming machinery is efficient, it is not perfect, as inappro-
priate expression of donor nuclei lineage-specific genes is
sometimes observed in the reprogrammed animal. The incorpo-
ration of histone H3.3 into the transplanted somatic nuclei is
thought to be partly responsible for this epigenetic memory. Oo-
cytes are ideal hosts for somatic nuclear transfer, as they do not
replicate DNA following this procedure. Amphibian oocytes are
able to induce the expression of stem cell genes in transferred
nuclei from mammalian cells, providing a model for the identifi-
cation of the molecules that mediate this process.
The ground-breaking studies of Yamanaka and colleagues
just 2 years ago (Takahashi and Yamanaka, 2006) demonstrated
that adult cells can be reprogrammed to a pluripotent state (in-
duced pluripotent stem cells [iPSCs]) by the ectopic expression
of four transcription factors. Whether or not similar mechanisms
are involved in the reprogramming of somatic nuclei by egg/oo-
cyte cytoplasm as in the transcription factor-mediated approach
will certainly be addressed in the future. At this year’s meeting,
Yamanaka (Kyoto University) reported that the addition of other
factors to the standard cocktail of four reprogramming factors
significantly increased the efficiency of reprogramming fibro-
blasts. Fibroblasts are clearly not the only cells that can be re-
programmed, as Yamanaka showed that iPSCs could be ob-
tained from keratinocytes, bronchial cells, stomach, and liver
(Aoi et al., 2008), and Jacob Hanna (Jaenisch laboratory, White-
head Institute for Biomedical Research) demonstrated the gen-
eration of iPSCs from B lymphocytes (Hanna et al., 2008).
Yamanaka also showed that iPSCs generated from these differ-
ent somatic tissues displayed similar, but not identical, gene ex-
pression patterns. Evaluation of the developmental potential of
these different iPSCs in vivo in chimeric mice revealed interesting
and unexpected differences. As reported previously, a high pro-
portion of chimeric mice (up to 50%) derived from iPSCs induced
with myc developed tumors. The tumor-forming potential may be
related to the cell of origin, to viral copy number, or to both, as he-
patocyte and stomach-derived iPSCs that contained fewer myc
viral integrations than those of fibroblast origin showed a much
lower incidence of tumor formation in chimeric mice. Although
these chimeric mice did not get tumors, they displayed a high
incidence of mortality by 1 year of life (Aoi et al., 2008). Chimeric
mice created with iPSCs from adult tail tip fibroblasts also showed
this mortality. The cause of death of these animals is not known,
but one hypothesis is incomplete reprogramming of the iPSCs.
These findings do raise a note of cautionand suggest that perhaps
not all iPSCs are reprogrammed to a fixed pluripotent state.
For iPSCs to be of value to basic and translational research, it is
essential that they are able to efficiently and reproducibly give rise
to differentiated cell types in culture. Genta Narazaki (Yamashita
laboratory, Kyoto University) demonstrated that different mouse
iPSC lines could efficiently differentiateand generate vascular cells
and cardiomyocytes using conditions previously optimized for
ESC differentiation (Narazaki et al., 2008). The kinetics of lineage
specification in the iPSC cultures was similar to that observed in
the ESC cultures, suggesting that the populations are similar withCell Stem Cell 3, September 11, 2008 ª2008 ISSCR 263
Cell Stem Cell
ISSCR: Meeting Reportrespect to their ability to respond to differentiation signals. Compa-
rable studies need to be carried out with human iPSCs.
There also exists the potential to convert cells directly from one
lineage to the next, without reverting back to a pluripotent stage.
Within this context, Thomas Graf (ICREA and Center for Genomic
Regulation) reviewed his studies demonstrating that it is possible
to convert B lymphocyte precursors to macrophages through the
ectopic expression of the myeloid transcription factor c/EBPa
(Xie et al., 2004). Expression of this same transcription factor in
pre-T cells also converts them into macrophages. As the expres-
sion of stem cell genes was not detected at any stage during the
conversion, Graf concluded that dedifferentiation was not involved
in the process but rather that the cells undergo a direct lineage
switch. Along the same lines, Douglas Melton (Harvard University)
addressed the question of lineage switching in the pancreas and
reported that the enforced expression of a transcription factor
cocktail in exocrine cells converted them to endocrine beta cells.
The reprogrammed cells displayed many of the hallmarks of beta
cells, including gene expression profiles, EM morphology, and
the capacity to partially reverse the hyperglycemia in diabetic
mice.Theconceptofdirect lineageconversionhighlightedbythese
presentations is likely tobesoonapplied tootherpopulations,mov-
ing a rapidly changing field in new and unanticipated directions.
Rudolf Jaenisch (Whitehead Institute for Biomedical Research)
concluded the meeting with the presentation of the Anne McLa-
ren Memorial lecture. He reported on studies that involved the
use of tetracycline-inducible vectors to drive expression of the re-
programming genes during the generation of iPSCs from fibro-
blasts. With this approach, he was able to demonstrate that the
reprogramming genes needed to be expressed for only 12 days
to generate iPSCs (Brambrink et al., 2008). The established kinet-
ics of reprogramming now enables the identification and charac-
terization of intermediate stages during the reprogramming pro-
cess. Jaenisch also stressed the need for much more detailed
characterization of iPSCs to determine the extent of variability be-
tween different iPSC lines and between iPSC lines and ESCs, for
developing technologies for the efficient genetic modification of
pluripotent cells, and for the establishment of robust differentia-
tion protocols to enable efficient and reproducible generation of
different functional cell types from these stem cell populations.
Concluding Remarks
With this report we have tried to convey the breadth and flavor of
the science presented at the meeting in Philadelphia and in doing
so hope to highlight the pace at which the field is moving and the
overall enthusiasm and excitement shared by all who attended.
There were numerous outstanding presentations that covered
the basic biology of different types of stem cells and provided
novel insights into how these cells are generated in vivo and
in vitro and on how cell-fate choices are affected by extrinsic
and intrinsic signaling networks. With respect to the therapeutic
promise of pluripotent stem cells, the take-home message ech-
oed by a number of speakers was the need for a better under-
standing of the mechanisms that govern lineage-specific differ-
entiation of these cells as well as their maturation to stable and
functional mature cells. It is only when we have achieved this
level of understanding that cell-based therapy using pluripotent
stem cells will become a safe and reliable option. Cell therapy us-
ing adult stem cells is already routinely performed for the hema-264 Cell Stem Cell 3, September 11, 2008 ª2008 ISSCRtopoietic system, and encouraging results were presented using
other tissue-specific stem cells. The demonstration of direct lin-
eage conversion in both the hematopoietic system and the pan-
creas provides a potentially exciting new therapeutic alternative
to stem cell transplantation. Findings presented at future meet-
ings will no doubt address this potential. Cancer stem cells
were prominent at the meeting, as there is growing enthusiasm
in the field that these cells will represent novel targets for the
development of new therapies for the treatment of a number of
different types of cancer. Given the dynamic nature of the field
of stem cell biology, it is impossible to predict what remarkable
discoveries will be made before the next meeting, but what is
certain is that there will be many. See you next year in Barcelona!
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